

NEIFELD REF.: TACT0010

IN RE: U.S. Patent 6,537,549 of Tobinick

Application serial no. 09/841,844, filed April 25, 2001

FOR: Cytokine antagonists for the treatment of localized disorders

Entity Status: small

37 CFR 1.7(e) FILING RECEIPT AND TRANSMITTAL LETTER WITH AUTHORIZATION TO CHARGE DEPOSIT ACCOUNT

1. THE COMMISSIONER IS HEREBY AUTHORIZED TO CHARGE ANY FEES WHICH MAY BE REQUIRED, OR CREDIT ANY OVERPAYMENT, TO DEPOSIT ACCOUNT NUMBER 50-2106.

2. FEES PAID HEREWITH BY EFS CREDIT CARD SUBMISSION: \$70

1.20(d) Statutory disclaimer 70.00 (small entity)

3. **THE FOLLOWING DOCUMENTS ARE SUBMITTED HEREWITH:**

37 C.F.R. 1.321(a) STATUTORY DISCLAIMER – 1page

Certification under 37 C.F.R. §3.73(b) – 1 page

4. **FOR INTERNAL NEIFELD IP LAW, PC USE ONLY**

USPTO CHARGES: \$140	FIRM CHARGES: \$300
CLIENT BILLING MATTER:	DESCRIPTION: FIRM CHARGE FOR
BANK ACCOUNT/Check: 6/540	filing statutory disclaimer.
G/L ACCOUNT: 5010	LAWYER: RWH

INITIALS OF PERSON WHO *ENTERED* ACCOUNTING DATA: RWH

ATTORNEY SIGNATURE (AUTHORIZING DEPOSIT ACCOUNT)

DATE: 12-26-2008

SIGNATURE:/RobertHahl#33,893/

Name: Robert .W. Hahl, Ph.D.

/RichardNeifeld#35,299/
RICHARD NEIFELD REG. NO. 35, 299